Mergers & Acquisitions
Varian Medical Systems announces intent to acquire ACCEL Instruments for $30 million
Published in Cancer Weekly, January 30th, 2007
The acquisition will enable Varian to offer products for delivering image-guided, intensity modulated proton therapy for selected cancer patients. Varian will invest approximately $30 million to acquire 100% of ACCEL, including its debt.
ACCEL has commissioned its newly developed superconducting medical cyclotron for proton therapy at the Paul Scherer Institute outside Zurich, Switzerland. Work is nearing completion on another...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-01-30)
More Articles from Cancer Weekly
- Cancer Therapy
Genetic factors are associated with head and neck cancer - Colon Cancer
Nuvelo initiates trial of rNAPc2 in metastatic colorectal cancer - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Hoshi University, Institute of Medicinal Chemistry - Cancer Gene Therapy
Investigators at Hanyang University, Department of Chemical Engineering target cancer gene therapy - Cancer Gene Therapy
Kanazawa University describes research in cancer gene therapy - Cancer Gene Therapy
New cancer gene therapy study results from Sapporo Medical University, Department of Pathology described - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
